Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

1.12
-0.0200-1.75%
Volume:67.80K
Turnover:74.57K
Market Cap:7.46M
PE:-0.24
High:1.14
Open:1.12
Low:1.05
Close:1.14
52wk High:10.33
52wk Low:0.6201
Shares:6.66M
Float Shares:5.42M
Volume Ratio:0.42
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7656
EPS(LYR):-8.3501
ROE:-660.08%
ROA:-95.77%
PB:1.61
PE(LYR):-0.13

Loading ...

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

GlobeNewswire
·
May 11

FibroBiologics boosts ATM equity offering capacity to USD 7.5 million

Reuters
·
May 06

Fibrobiologics Inc - Increases Atm Offering to Aggregate $7.5 Mln on May 5, 2026 - SEC Filing

THOMSON REUTERS
·
May 06

FibroBiologics CEO Issues Letter to Shareholders

GlobeNewswire
·
May 05

FibroBiologics Grants Stock Options to Key Executives

TIPRANKS
·
May 05

FibroBiologics grants CEO 92,410 stock options, executives 61,607 each at $1.38

Reuters
·
May 05

FibroBiologics reports preclinical burn-wound data for fibroblast spheroid therapy

Reuters
·
May 05

FibroBiologics Cut to Hold From Buy by Maxim Group

Dow Jones
·
May 04

FibroBiologics releases CYWC628 drug product for Phase 1/2 diabetic foot ulcer trial

Reuters
·
May 04

Fibrobiologics Inc - Phase 1/2 Trial to Evaluate Cywc628 Safety, Tolerability, and Efficacy in Dfu Patients

THOMSON REUTERS
·
May 04

Fibrobiologics Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
May 04

FibroBiologics Warns of ‘Going Concern’ Risk as Losses Mount and Funding Outlook Darkens

TIPRANKS
·
May 02

FibroBiologics Launches New At-The-Market Equity Offering

TIPRANKS
·
May 02

FibroBiologics enters $6.15 million at-the-market equity offering agreement with H.C. Wainwright

Reuters
·
May 02

Fibrobiologics Inc - Enters Atm Offering Agreement to Sell up to $6.15 Mln of Common Stock - SEC Filing

THOMSON REUTERS
·
May 02

FibroBiologics reports Q1 net loss roughly ($5M)

TIPRANKS
·
May 01

FibroBiologics, Inc. - Common Stock Q1 EPS $(1.33), Inline

Benzinga Earnings
·
May 01

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 01

Fibrobiologics Q1 net loss widens to $5 million; R&D expense climbs to $2.95 million

Reuters
·
May 01

FibroBiologics to present CYPS317 psoriasis preclinical data at Society for Investigative Dermatology meeting

Reuters
·
Apr 30